Beijing Foyou Pharma CO.,LTD

SHSE:601089 Stock Report

Market Cap: CN¥7.4b

Beijing Foyou PharmaLTD Past Earnings Performance

Past criteria checks 3/6

Beijing Foyou PharmaLTD has been growing earnings at an average annual rate of 17.6%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 7.3% per year. Beijing Foyou PharmaLTD's return on equity is 14.8%, and it has net margins of 14.9%.

Key information

17.6%

Earnings growth rate

10.3%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate7.3%
Return on equity14.8%
Net Margin14.9%
Next Earnings Update01 Apr 2025

Recent past performance updates

Investors Shouldn't Be Too Comfortable With Beijing Foyou PharmaLTD's (SHSE:601089) Earnings

Apr 08
Investors Shouldn't Be Too Comfortable With Beijing Foyou PharmaLTD's (SHSE:601089) Earnings

Recent updates

A Look At The Fair Value Of Beijing Foyou Pharma CO.,LTD (SHSE:601089)

Nov 18
A Look At The Fair Value Of Beijing Foyou Pharma CO.,LTD (SHSE:601089)

Does Beijing Foyou PharmaLTD (SHSE:601089) Have A Healthy Balance Sheet?

Sep 29
Does Beijing Foyou PharmaLTD (SHSE:601089) Have A Healthy Balance Sheet?

Investors Shouldn't Be Too Comfortable With Beijing Foyou PharmaLTD's (SHSE:601089) Earnings

Apr 08
Investors Shouldn't Be Too Comfortable With Beijing Foyou PharmaLTD's (SHSE:601089) Earnings

Revenue & Expenses Breakdown

How Beijing Foyou PharmaLTD makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SHSE:601089 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 243,4245101,345430
30 Jun 243,3655291,282406
31 Mar 243,3235081,314364
31 Dec 233,3404891,350353
30 Sep 233,3374881,428288
30 Jun 233,3274831,481270
31 Mar 233,3124671,496259
31 Dec 223,2404391,494238
30 Sep 223,1603851,484228
30 Jun 223,0593571,461204
31 Mar 222,9753401,446191
31 Dec 212,8383141,401177
31 Dec 202,5352631,342138
31 Dec 192,4252191,398169
31 Dec 182,0202001,094140

Quality Earnings: 601089 has a high level of non-cash earnings.

Growing Profit Margin: 601089's current net profit margins (14.9%) are higher than last year (14.6%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 601089's earnings have grown by 17.6% per year over the past 5 years.

Accelerating Growth: 601089's earnings growth over the past year (4.6%) is below its 5-year average (17.6% per year).

Earnings vs Industry: 601089 earnings growth over the past year (4.6%) exceeded the Pharmaceuticals industry -2.5%.


Return on Equity

High ROE: 601089's Return on Equity (14.8%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/28 22:02
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Beijing Foyou Pharma CO.,LTD is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution